Column Group II GP, LP

CIK 1645333 · last filed 2022-05-23

Column Group II GP, LP is a corporate insider who has filed 9 SEC Form 4 insider transactions across 4 companies since 2018. The most recent filing shows the insider bought $5.3M of NGM on May 23, 2022. Across all open-market trades the lifetime net is −$182.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $89.9M across reported positions. The firm reports its address in San Francisco, CA. 94 SEC filings were submitted jointly with COLUMN GROUP II, LP.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$89.89M

Companies

4

Total Filings

9

Lifetime Open-Market Net

-$182.12M

Filer Profile

Reported Address
1700 OWENS STREET, SUITE 500
SAN FRANCISCO, CA 94158
Phone
(415) 865-2050
State of Incorporation
DE
Related Filers
COLUMN GROUP II, LP — 94 joint filings, latest 2024-12-23
PONOI CAPITAL, LP — 85 joint filings, latest 2024-12-23
Ponoi Management, LLC — 85 joint filings, latest 2024-12-23
Tim Kutzkey — 84 joint filings, latest 2024-12-23
Ponoi Capital II, LP — 80 joint filings, latest 2024-12-23
Ponoi II Management, LLC — 80 joint filings, latest 2024-12-23
COLUMN GROUP L P — 70 joint filings, latest 2024-04-08
Column Group Management LP — 64 joint filings, latest 2024-04-08
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NGM BIOPHARMACEUTICALS INC (NGM) Delisted 10%+ Owner 11,118,333 $1.54 $17.12M $16.66M 2 2022-05-23
ORIC 10%+ Owner 3,855,883 $12.04 $46.42M $0 1 2021-11-16
RAPT Therapeutics, Inc. (RAPT) Delisted 10%+ Owner 326,346 $58.01 $18.93M -$198.78M 3 2021-08-24
RCUS 10%+ Owner 1,767,676 $24.59 $43.47M $0 1 2018-03-19

Recent Filings

9 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-05-23 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +397,000 $5.30M EDGAR
2021-11-16 ORIC Mixed −5,049,345 $1.33M EDGAR
2021-08-24 RAPT Therapeutics, Inc. (RAPT) Delisted Sell (S) −957,460 -$29.97M EDGAR
2020-09-23 RAPT Therapeutics, Inc. (RAPT) Delisted Sell (S) −5,472,000 -$168.81M EDGAR
2020-08-17 NGM BIOPHARMACEUTICALS INC (NGM) Delisted Buy (P) +643,130 $11.35M EDGAR
2020-06-22 RAPT Therapeutics, Inc. (RAPT) Delisted Other (J) $0 EDGAR
2019-04-02 U −59,786,478 -$349.75M
2018-03-19 RCUS Conv (C) +24,785,950 $0 EDGAR
2016-09-22 Buy (P) +4,000,000 $25.00M
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.